Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The China's State Food and Drug Administration (SFDA) has approved Tianyin Pharmaceutical's anti-diabetic drug Gliclazide Tablets (80mg formulation).
Subscribe to our email newsletter
Gliclazide is an oral sulfonylurea hypoglycemic agent which stimulates insulin secretion which stimulates beta cells of the islet of Langerhans in the pancreas to release insulin.
Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes of stable, mild, non-ketosis prone, maturity-onset or adult type.
The company intends to launch the product in July 2011.
It has been marketed as Glyloc and Reclide in India and Diamicron in Canada.